InsiderTrades

Form 4 for DNA Ginkgo Bioworks Holdings, Inc.

Accepted 2021-09-22 00:00:00 ET · period of report 2021-09-16 · accession 0000899243-21-037215 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
D 2021-09-22 2021-09-16 DNA Eagle Equity Partners III, LLC Dir, 10%, *Dir by Deputization D - Sale to Iss — -11.53M 31.59M -27% —
D 2021-09-22 2021-09-16 DNA Eagle Equity Partners III, LLC Dir, 10%, *Dir by Deputization M - OptEx — -43.12M 0 -100% —
D 2021-09-22 2021-09-16 DNA Eagle Equity Partners III, LLC Dir, 10%, *Dir by Deputization A - Grant $10.00 +19.25M 19.25M New +$192.50M
D 2021-09-22 2021-09-16 DNA Eagle Equity Partners III, LLC Dir, 10%, *Dir by Deputization D - Sale to Iss — -1.93M 17.32M -10% —

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Class A Common Stock 2021-09-16 D D 11,534,052 — 31,590,948 D — — (F1) In connection with the closing (the "Closing") of the business combination (the "Business Combination") between the Issuer (which was formerly known as Soaring Eagle Acquisition Corp. or "Soaring Eagle") and Ginkgo Bioworks, Inc. ("Ginkgo"), among other things, each share of Soaring Eagle's Class B ordinary shares converted pursuant to the terms of such shares into shares of the Issuer's Class A common stock on a one-for-one basis. Simultaneously, pursuant to the Sponsor Support Agreement, dated as of May 11, 2021 (the "Sponsor Support Agreement") between the Reporting Person, Ginkgo, Soaring Eagle and certain other shareholders, the Reporting Person forfeited to the Issuer at no cost 11,534,052 shares of the Issuer's Class A common stock, which was exempted pursuant to Rule 16b-3(e) under the Securities Exchange Act of 1934, as amended (the "Exchange Act").
2 Derivative Class B Ordinary Shares 2021-09-16 M D 43,125,000 — 0 D — · — to — 43,125,000 Class A Common Stock (F1) In connection with the closing (the "Closing") of the business combination (the "Business Combination") between the Issuer (which was formerly known as Soaring Eagle Acquisition Corp. or "Soaring Eagle") and Ginkgo Bioworks, Inc. ("Ginkgo"), among other things, each share of Soaring Eagle's Class B ordinary shares converted pursuant to the terms of such shares into shares of the Issuer's Class A common stock on a one-for-one basis. Simultaneously, pursuant to the Sponsor Support Agreement, dated as of May 11, 2021 (the "Sponsor Support Agreement") between the Reporting Person, Ginkgo, Soaring Eagle and certain other shareholders, the Reporting Person forfeited to the Issuer at no cost 11,534,052 shares of the Issuer's Class A common stock, which was exempted pursuant to Rule 16b-3(e) under the Securities Exchange Act of 1934, as amended (the "Exchange Act").
3 Derivative Private Placement Warrants 2021-09-16 A A 19,250,000 $10.00 19,250,000 D $11.50 · — to — 19,250,000 Class A Common Stock (F2) The private placement warrants were acquired from the Issuer in connection with its initial public offering, the terms of which are described under the heading "Description of Securities" in the Issuer's registration statement on Form S-1 (File No. 333-251661). Each private placement warrant is exercisable for one share of Class A Common Stock at an exercise price of $11.50 per share, subject to certain adjustments. The private placement warrants are reported as acquired for purposes of Section 16 of the Exchange Act concurrently with the Closing, because they did not become derivative securities until such date based on the terms of their exercisability.
4 Derivative Private Placement Warrants 2021-09-16 D D 1,925,000 — 17,325,000 D $11.50 · — to — 1,925,000 Class A Common Stock (F3) Pursuant to the Sponsor Support Agreement, the Reporting Person forfeited to the Issuer at the Closing 10% of the private placement warrants it then held at no cost, which was exempted pursuant to Rule 16b-3(e) under the Exchange Act. (F2) The private placement warrants were acquired from the Issuer in connection with its initial public offering, the terms of which are described under the heading "Description of Securities" in the Issuer's registration statement on Form S-1 (File No. 333-251661). Each private placement warrant is exercisable for one share of Class A Common Stock at an exercise price of $11.50 per share, subject to certain adjustments. The private placement warrants are reported as acquired for purposes of Section 16 of the Exchange Act concurrently with the Closing, because they did not become derivative securities until such date based on the terms of their exercisability.